Discover Koneksa

Obtain a PDF overview of our company and offerings.

Resources
Announcing $45M Series C Financing and Appointment of John Wagner as Chief Medical Officer

Today, we announced the completion of our Series C financing round, as well as the appointment of industry leader John A. Wagner, M.D., Ph.D. as our first Chief Medical Officer. The full announcement is available here.

We are delighted to welcome AyurMaya, an affiliate of Matrix Capital Management, as well as Takeda Ventures and Velosity Capital, to our existing major investors who also joined the round: McKesson Ventures, Merck Global Health Innovation Fund, Novartis (dRx Capital), Spring Mountain Capital and Waterline Ventures. Matrix Senior Managing Director Karan Takhar will join our Board of Directors.Dr. Wagner’s arrival corresponds with the goals of the funding: to expand our digital biomarker technology platform, to develop our self-service platform, and to accelerate our expansion and capabilities.

As part of the announcement, some of our NYC-based Koneksa colleagues were able to gather and celebrate in person – as the rest of our workforce joined the celebration remotely – when our news was featured on the NASDAQ marquee in Times Square!

See additional coverage in:

 

Support Your Clinical Trial with Our Tech & Team
Share your needs and we’ll be in touch soon.